Pulmonary Hypertension is a serious and unrelenting pulmonary vascular disorder that affects the functional quality of patients significantly and decrease the lifespan. Diagnosis at early stage may save many life as numbers of therapeutic options are available. Etiological diagnosis of PAH is very important as everyone demands separate therapeutic protocol and may curable if diagnosed in time. As the symptoms are often subtle in the early stage of disease it is imperative that physician should be aware of the manifestation of condition. A routine work up may be carried out in well equipped Hospital at periphery in many affluent and advanced countries. In developing countries like India work up can only be done in a tertiary care centre under the supervision of pulmonologist and cardiologist. In our study we had tried to focus the etiological  diagnosis of PAH as availability of resources in our setup to give a brief idea in this population group. Comparative young age group were choosen as the stage of disease in this age group shows significant reversibility with proper treatment. 

Keywords: Etiology of Pulmonary Hypertension, Pulmonary Hypertension, Primary Pulmonary Hypertension, Secondary Pulmonary Hypertension.

1. Barst R.J., Gibbs S.R., Ghofrani H.A., et al. (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl):78–84.
2. OpenUrlMcLaughlin V.V.,Archer S.L., Badesch D.B.,et al.(2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J Am Coll Cardiol 53:1573–1619.
3. OpenUrlHoeper M.M., Barbera J.A., Channick R.N.,et al.(2009) Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54(Suppl):85–96.
4. OpenUrlAbraham W.T., Raynolds M.V.Gottschall B.,et al.(1995) Importance of angiotensin-converting enzyme in pulmonary hypert-ension. Cardiology 86(Suppl 1):9–15.
5. OpenUrlBristow M.R., Minobe W. Rasmussen R., et al.(1992) Beta-adrenergic neuro effector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89:803–815.
6. Kalra P.R., Moon J.C., Coats A.J.(2002) Do results of the ENABLE (Endothelin Antagonists    Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85↵
7. Bursi F., McNallan S.M., Redfield M.M., et al.(2012) Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 59:222–231.
8. OpenUrlKjaergaard J.Akkan D.Iversen K.K.,et al.(2007) Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 99:1146–OpenUrl
9. Leung C.C. Moondra V.Catherwood E.et al.(2010) Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 106:284–286.
10. OpenUrlRosjo H.Omland T.(2009) New statistical methods for the evaluation of cardiovascular risk markers: what the clinician should know. Clin ScienceOpenUrl
11. Lam C.S., Roger V.L. Rodeheffer R.J.et al.(2009) Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol 53OpenUrl
12. Chung L.Liu J.Parsons L.et al.(2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138:1383–1394.
13. OpenUrlFarber H.W.Foreman A.J.Miller D.P. McGoon M.D.(2011) REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 17:56–64.
14. OpenUrlFrost A.E.Badesch D.B.Barst R.J.et al(2011) The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest 139:128–137.
15. OpenUrlKrowka M.J.Miller D.P.Barst R.J.et al.(2012) Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 141:906–915.
16. OpenUrlShapiro S.Traiger G.L.Turner M.McGoon M.D. Wason P.Barst R.J.(2012) Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 141:363–373.
17. OpenUrlEscribano-Subias P.Blanco I.Lopez-Meseguer M.et al.(2012) Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 40:596–603.
18. OpenUrlLing Y.Johnson M.K.Kiely D.G.et al. (2012) Changing demographics, epidemiology and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186:790–796.
19. OpenUrlJiang X.Humbert M.Jing Z.C.(2012) in Pulmonary Vascular Disorders. Prog Respir Res, Idiopathic pulmonary arterial hypertension and its prognosis in the modern management era in developed and developing countries, eds Humbert M., Souza R., Simonneau G. (Karger, Basel), pp 85–93.
20. Zhang R., Dai L.Z.Xie W.P.et al.(2011) Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest 140:301–309.
21. OpenUrlKane G.C. Maradit-Kremers H.Slusser J.P. Scott C.G.Frantz R.P.McGoon M.D. (2011) Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 139:1285–129OpenUrl .

Lina Mukherjee

Resident at Cardiology, R.G.KAR Medical College, Kolkata, West Bengal, India